Ennio Tasciotti

PAC-MAN

Chronic Pain post-COVID

Project Coordinator:

Ennio Tasciotti, IRCCS San Raffaele, Italy

Project Partners:

Luda Diatchenko, McGill University, Canada

César Fernández-de-las-Peñas, Universidad Rey Juan Carlos, Spain

Andrea Fanelli, Redirect Pain, Italy

Gisèle Pickering, University Hospital of Clermont-Ferrand, France

Sam Eldabe, The James Cook University Hospital, Hospitals NHS Foundation Trust, UK

Lars Arendt-Nielsen, Aalborg University and Aalborg University Hospital, Denmark

Jean-Pierre Van Buyten, Multidisciplinary Pain Center. Vitaz hospital. Sint – Niklaas, Belgium

Massimo Allegri, Centre Lemanique d'antalgie et neuromodulation & Ensemble Hospitalier de la côte - Morges, Switzerland

Carolina Muscoli, Università Magna Graecia, Italy

Pablo Ingelmo, Montreal Childrens Hospital, Canada

Assaf Zinger, Technion- Israel Institute of Technology, Israel

Dragan Primorac, St. Catherine Hospital, Croatia

Filippo Sertorio, Farmaceutici Procemsa spa, Italy

Nicoletta Marchesi, REDYNEUHEART SRL, Italy

Gordan Lauc, Genos Ltd, Croatia

Marina Lusic, Heidelberg University Hospital, Germany

Thomas Volk, Saarland University, Germany

Over 200 million patients worldwide suffer from fatigue, widespread muscle pain, joint and chest pain as a consequence of COVID-19 infection. Little is known about the onset and pathophysiology of these conditions, leaving doctors at loss for the diagnosis and treatments of these patients. With this in mind, we formed the Pain After Covid-Multidisciplinary Action Network (PAC-MAN), a multidisciplinary consortium to advance knowledge on post-COVID chronic pain, discuss the current clinical gaps, and develop potential solutions for these pressing clinical issues.

We will address all these shortcomings and clinical needs by defining a roadmap of activities aiming at raising awareness and building a world-wide network of scientists, clinicians and entrepreneurs committed not only to solving the issue of chronic pain post-COVID, but also to evaluating and defining short and long-term solutions for other chronic pain syndromes.

To address this multifaceted problem and to ensure a comprehensive approach, we included in our network professionals with complementary expertise in medicine, science and technology to better understand chronic pain syndrome's pathophysiology, to discover new biomarkers and to explore clinical solutions through the synergy between new diagnostic tools (genomics and glycomics), innovative biomedical technologies (nanomedicine and neuromodulation), and alternative therapeutic regimens (drug repositioning and nutraceuticals).